Impact of liver tumour burden, alkaline phosphatase elevation, and target lesion size on treatment outcomes with ¹⁷⁷Lu-Dotatate: an analysis of the NETTER-1 study.

ABSTRACT:

Purpose

To assess the impact of baseline liver tumour burden, alkaline phosphatase (ALP) elevation, and target lesion size on treatment outcomes with ¹⁷⁷Lu-Dotatate.

Methods

In the phase 3 NETTER-1 trial, patients with advanced, progressive midgut neuroendocrine tumours (NET) were randomised to 177Lu-Dotatate (every 8 weeks, four cycles) plus octreotide long-acting release (LAR) or to octreotide LAR 60 mg. Primary endpoint was progression-free survival (PFS). Analyses of PFS by baseline factors, including liver tumour burden, ALP elevation, and target lesion size, were performed using Kaplan-Meier estimates; hazard ratios (HRs) with corresponding 95% CIs were estimated using Cox regression.

Results

Significantly prolonged median PFS occurred with ^177</

SUBMITTER: Strosberg J 

PROVIDER: S-EPMC7396396 | biostudies-literature | 2020 Sep

REPOSITORIES: biostudies-literature